---
type: "Symbol"
title: "HilleVax (HLVX.US) — Community Discussions"
description: "Community discussions about this stock, including analyst opinions, earnings analysis, and investment strategies from verified financial professionals and active investors."
locale: "en"
url: "https://longbridge.com/en/quote/HLVX.US/topics.md"
symbol: "HLVX.US"
parent: "https://longbridge.com/en/quote/HLVX.US.md"
count: 1
datetime: "2026-03-12T02:15:07.590Z"
locales:
  - [en](https://longbridge.com/en/quote/HLVX.US/topics.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/HLVX.US/topics.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/HLVX.US/topics.md)
---

# HilleVax (HLVX.US) — Community Discussions

### [国产疫苗「逆风翻盘」](https://longbridge.com/en/topics/11100538.md)

- Author: [药械Talks](https://longbridge.com/en/profiles/6059509.md)
- Datetime: 2024-01-14T03:45:32.000Z
- Comments: 0
- 对外授权 “出海” 的风，还是吹到了疫苗领域。近日，$Kanghua Biological(300841.SZ) 将重组六价诺如病毒疫苗除中国地区（含港澳台）以外的海外权益授权给 HilleVax 公司，双方达成最高合计 2.705 亿美元的交易金额（首付款 1500 万美元 + 里程碑款项 2.555 亿美元）。这是国产创新疫苗首次授权出海，具有里程碑意义。尽管相比火热 “出海” 的 ADC、小

## References

- [HilleVax (HLVX.US)](https://longbridge.com/en/quote/HLVX.US.md)


> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/HLVX.US/topics.md) | [繁體中文](https://longbridge.com/zh-HK/quote/HLVX.US/topics.md)